Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by BOGDAN A CZERNIAK and CHARLES CHUANHAI GUO.
BOGDAN A CZERNIAK
Connection Strength
15.215
CHARLES CHUANHAI GUO
  1. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat Rev Urol. 2024 07; 21(7):391-405.
    View in: PubMed
    Score: 0.941
  2. Recent Advances in the Classification of Bladder Cancer - Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors. Bladder Cancer. 2023; 9(1):1-14.
    View in: PubMed
    Score: 0.887
  3. Reprint of: somatic-type malignancies in testicular germ cell tumors. Hum Pathol. 2023 03; 133:102-114.
    View in: PubMed
    Score: 0.882
  4. Updates of Prostate Cancer from the 2022 World Health Organization Classification of the Urinary and Male Genital Tumors. J Clin Transl Pathol. 2023 Jan-Mar; 3(1):26-34.
    View in: PubMed
    Score: 0.874
  5. Molecular Taxonomy and Immune Checkpoint Therapy in Bladder Cancer. Surg Pathol Clin. 2022 Dec; 15(4):681-694.
    View in: PubMed
    Score: 0.859
  6. Somatic-type malignancies in testicular germ cell tumors. Hum Pathol. 2022 09; 127:123-135.
    View in: PubMed
    Score: 0.843
  7. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020 06 16; 10(1):9743.
    View in: PubMed
    Score: 0.731
  8. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.
    View in: PubMed
    Score: 0.677
  9. Bladder Cancer in the Genomic Era. Arch Pathol Lab Med. 2019 06; 143(6):695-704.
    View in: PubMed
    Score: 0.663
  10. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016 10; 70(4):611-620.
    View in: PubMed
    Score: 0.544
  11. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Mar 20; 507(7492):315-22.
    View in: PubMed
    Score: 0.470
  12. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum Pathol. 2012 May; 43(5):644-9.
    View in: PubMed
    Score: 0.399
  13. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol. 2011 Jan; 42(1):11-7.
    View in: PubMed
    Score: 0.375
  14. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009 Oct; 40(10):1448-52.
    View in: PubMed
    Score: 0.339
  15. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol. 2009 Jul; 22(7):866-71.
    View in: PubMed
    Score: 0.338
  16. Micropapillary variant of urothelial carcinoma in the upper urinary tract: a clinicopathologic study of 11 cases. Arch Pathol Lab Med. 2009 Jan; 133(1):62-6.
    View in: PubMed
    Score: 0.330
  17. Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases. Hum Pathol. 2024 Nov; 153:105673.
    View in: PubMed
    Score: 0.247
  18. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol. 2024 06; 148:1-6.
    View in: PubMed
    Score: 0.239
  19. Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis. Cell Rep. 2024 May 28; 43(5):114146.
    View in: PubMed
    Score: 0.239
  20. Inferring Bladder Cancer Evolution from Mucosal field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping. Res Sq. 2024 Apr 10.
    View in: PubMed
    Score: 0.238
  21. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. 2022 08 04; 158(2):263-269.
    View in: PubMed
    Score: 0.212
  22. Erratum: The origin of bladder cancer from mucosal field effects. iScience. 2022 Jul 15; 25(7):104715.
    View in: PubMed
    Score: 0.211
  23. The origin of bladder cancer from mucosal field effects. iScience. 2022 Jul 15; 25(7):104551.
    View in: PubMed
    Score: 0.210
  24. Somatic-type Malignancies in Testicular Germ Cell Tumors: A Clinicopathologic Study of 63 Cases. Am J Surg Pathol. 2022 01 01; 46(1):11-17.
    View in: PubMed
    Score: 0.203
  25. Secondary tumors of the bladder: A survival outcome study. Ann Diagn Pathol. 2020 Oct; 48:151593.
    View in: PubMed
    Score: 0.185
  26. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol. 2020 07 07; 154(2):208-214.
    View in: PubMed
    Score: 0.183
  27. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
    View in: PubMed
    Score: 0.182
  28. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 02 19; 26(8):2241-2256.e4.
    View in: PubMed
    Score: 0.167
  29. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 09; 79:57-65.
    View in: PubMed
    Score: 0.158
  30. High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol. 2017 09; 67:126-133.
    View in: PubMed
    Score: 0.150
  31. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506.
    View in: PubMed
    Score: 0.147
  32. Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. Pathol Oncol Res. 2018 Jan; 24(1):153-159.
    View in: PubMed
    Score: 0.147
  33. Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017 01 19; 7:40714.
    View in: PubMed
    Score: 0.144
  34. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016 Oct; 12:105-117.
    View in: PubMed
    Score: 0.140
  35. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec; 46(12):1808-14.
    View in: PubMed
    Score: 0.131
  36. Adenocarcinoma of the urinary bladder. Am J Clin Exp Urol. 2015; 3(2):51-63.
    View in: PubMed
    Score: 0.130
  37. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71.
    View in: PubMed
    Score: 0.124
  38. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014 Jul; 45(7):1466-72.
    View in: PubMed
    Score: 0.118
  39. Urothelial tumors of the urinary bladder in young patients: a clinicopathologic study of 59 cases. Arch Pathol Lab Med. 2013 Oct; 137(10):1337-41.
    View in: PubMed
    Score: 0.115
  40. Relationship between primary and metastatic testicular germ cell tumors: a clinicopathologic analysis of 100 cases. Hum Pathol. 2013 Oct; 44(10):2220-6.
    View in: PubMed
    Score: 0.113
  41. Small cell carcinoma of the kidney: a clinicopathologic study of 14 cases. Hum Pathol. 2011 Nov; 42(11):1792-8.
    View in: PubMed
    Score: 0.101
  42. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol. 2011 Jan; 42(1):146-50.
    View in: PubMed
    Score: 0.094
  43. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol. 2009 Aug; 33(8):1173-8.
    View in: PubMed
    Score: 0.086
  44. Tumor-to-tumor metastasis: report of 2 cases of metastatic carcinoma to angiomyolipoma of the kidney. Arch Pathol Lab Med. 2008 Jun; 132(6):1016-20.
    View in: PubMed
    Score: 0.079
  45. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
    View in: PubMed
    Score: 0.057
  46. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.
    View in: PubMed
    Score: 0.053
  47. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797.
    View in: PubMed
    Score: 0.052
  48. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.
    View in: PubMed
    Score: 0.050
  49. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606.
    View in: PubMed
    Score: 0.050
  50. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021 09; 206(3):548-557.
    View in: PubMed
    Score: 0.048
  51. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 06; 37(6):354.e19-354.e26.
    View in: PubMed
    Score: 0.042
  52. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583.
    View in: PubMed
    Score: 0.037
  53. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017 10; 72(4):641-649.
    View in: PubMed
    Score: 0.037
  54. Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget. 2017 May 23; 8(21):34205-34222.
    View in: PubMed
    Score: 0.037
  55. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017 05; 119(5):684-691.
    View in: PubMed
    Score: 0.036
  56. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34.
    View in: PubMed
    Score: 0.031
  57. Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases. Hum Pathol. 2010 Jun; 41(6):832-7.
    View in: PubMed
    Score: 0.022
  58. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.